Neue Plasminogen-Aktivatoren: eine klinische Übersicht

A. M. Ross

doi:10.1055/s-0038-1660417

Hämostaseologie, Table of Contents

Hamostaseologie 1999; 19(04): 182-189
DOI: 10.1055/s-0038-1660417

Übersichtsarbeit/Review Article

Schattauer GmbH

Neue Plasminogen-Aktivatoren: eine klinische Übersicht

A. M. Ross

¹Cardiovascular Research Institute, George Washington University, Washington D. C, USA

› Author Affiliations

Abstract

Zusammenfassung

Der Schlüssel zum Erhalt von Myokardgewebe und einer höheren Überlebensrate bei akutem Herzinfarkt ist eine rasche Wiederherstellung der Durchgängigkeit der Infarktarterie. Das Verständnis dieses Zusammenhangs war Ausgangspunkt für die Anwendung der Gentechnik zur Entwicklung neuer Plasminogen-Aktivatoren mit speziellen klinischen Eigenschaften. Diese neuartigen Aktivatoren sollten zu einer rascheren und auch vollständigeren Perfusion führen und gleichzeitig ein geringeres Risiko für Blutungen und intrazerebrale Blutungen aufweisen. In diesem Übersichtsbeitrag werden die pharmakologischen Profile und die klinischen Eigenschaften verschiedener neuer Plasminogen-Aktivatoren, die gentechnisch hergestellt werden und von humanem Gewebe-Plasminogen-Aktivator bzw. aus tierischen oder bakteriellen Proteinen abgeleitet sind, dargelegt.

Schlüsselwörter

Thrombolyse - Plasminogen-Aktivatoren - akuter Herzinfarkt - TNK-tPA

Full Text

References

Literatur
1 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
2 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
3 Simes R.J, Topol E.J, Holmes Jr D.R, White H.D, Rutsch W.R, Vahanian A, Simoons M.L, Morris D, Betriu A, Califf R.M, Ross A.M. for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 1995; 91: 1923-8.
4 Ross A.M, Coyne K.S, Moreyra E, Reiner J.S, Greenhouse S.W, Walker P.L, Simoons M.L, Draoui Y.C, Califf R.M, Topol E.J, Van de Werf F, Lundergan C.F. for the GUSTO-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation 1998; 97: 1549-56.
5 Collen D. Thrombolytic therapy. Thromb Haemost 1997; 78: 742-6.
6 Lefkovits J, Topol E.J. Future directions in thrombolysis for myocardial infarction: what are the unanswered questions?. Coron Art Dis 1994; 5: 306-16.
7 Huber K, Maurer G. Thrombolytic therapy in acute myocardial infarction. Sem Thromb Hemost 1996; 22: 15-26.
8 Van de Werf F. TNK-tPA: Results of the phase II trials. TIMI 10B and ASSENT-1 Presentation at the XIX Congress of the European Society of Cardiology, August 24-28,1997, Stockholm, Schweden.
9 Ross A.M. New thrombolytic agents. J Inter-vent Cardiol 1997; 10: 395-9.
10 Smalling R.W. Molecular biology of plasminogen activators: what are the clinical implications of drug design?. Am J Cardiol 1996; 78 suppl. 12A 2-7.
11 Smalling R.W, Bode C, Kalbfleisch J. et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-32.
12 Bode C, Smalling R.W, Berg G, Burnett C, Lorch G, Kalbfleisch J.M, Chernoff R, Christie L.G, Feldman R.L, Seals A.A, Weaver W.D. for the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891-8.
13 The GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
14 White H.D. Thrombolytic therapy and equivalence trials. J Am Coll Cardiol 1998; 31: 494-6.
15 Gurbel P.A, Serebruany V.L, Shustov A.R, Bahr R.D, Carpo C, Ohman E.M, Topol E.J. for the GUSTO-III Investigators. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998; 31: 1466-73.
16 Stringer K.A. Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996; 16 (Suppl. 02) 119S-26S.
17 Koster R.W, Cohen A.F, Hopkins G.R. et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994; 72: 740-4.
18 Cutler D, Bode C, Runge M.S. The promise of new genetically engineered plasminogen activators. J Vase Interven Radiol 1995; 6: 3S-7S.
19 Sasahara A.A, Barker W.M, Weaver W.D. et al. Clinical studies with the new glycosylated recombinant prourokinase. J Vase Interv Radiol 1995; 6 suppl. 84S-93S.
20 Spiecker M, Meyer J. Prourokinase für die Infarkttherapie. (Prourokinase for treatment of acute myocardial infarction.) Herz 1994; 19: 326-35.
21 Vermeer F, Bär F, Windeler J. et al. Saruplase, a new fibrin specific thrombolytic agent: final results of the PASS study (1689 patients). Circulation 1993; 88: 1-292.
22 Tebbe U, Windeier J, Boesl I. et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (Saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis with Saruplase. J Am Coll Cardiol 1995; 26: 365-73.
23 Bär F.W, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spieker M, Macaya C, Hanssen M, Heras M, Boland J.P, Morice M-C, Dunn F.G, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen A.J, Klein W, Windeier J, Hopkins G, Barth H, von Fisenne M.J.M. for the SESAM Study Group. Comparison of Saruplase and alteplase in acute myocardial infarction. Am J Cardiol 1997; 79: 727-32.
24 PRIMI Trial Study Group. Randomized double-blind trial of recombinant pro-uroki-nase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
25 Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins G.R, Fennell W, Betriu A, Ruda M, Mlczoch J. Randomized, double-blind study comparing Saruplase with Streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. J Am Coll Cardiol 1998; 31: 487-93.
26 Bode C, Peter K, Nordt T. et al. New developments in thrombolytic therapy. Fibrinolysis & Proteolysis 1997; 11 (Suppl. 01) 109-14.
27 Bode C, Runge M.S, Schonermark S. et al. Conjugation to an antifibrin Fab’ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 1990; 81: 1974-80.
28 Keyt B.A, Paoni N.F, Refino C.J, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett W.F. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-4.
29 Topol E.J. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97: 211-8.
30 DeMarco E, Rebuzzi A.G, Quaranta G, van de Greef W, Kol A, Biasucci L.G, Maseri A, Andreotti F. Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction. Eur Heart J 1998; 19 suppl. 5.
31 Cannon C.P, McCabe C.H, Gibson C.M, Ghali M, Sequeira R.F, McKendall G.R, Breed J, Modi N.B, Fox N.L, Tracy R.P, Love T.W. Braunwald and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95: 351-6.
32 Cannon C.P, Gibson C.M, McCabe C.H, Adgey A.A, Schweiger M.J, Sequeira R.F, Grollier G, Giugliano R.P, Frey M, Mueller H.S, Steingart R.M, Weaver W.D, Van de Werf F, Braunwald E. for the TIMI IOB investigators. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998; 98: 2805-14.
33 Giugliano R.P, Cannon C.P, McCabe C.H, Van de Werf F, Braunwald E. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: results from TIMI 10B and ASSENT I. Circulation 1997; 96 suppl. I 1-535.
34 Gibson C.M, Cannon C.P, Daley W.L, Dodge J.T, Alexander B, Marble S.J, McCabe C, Raymond L, Fortin T, Poole W.K, Braunwald E. for the TIMI 4 Study Group. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88.
35 Gibson M. A randomized prospective comparison of t-PA with TNK using the TIMI frame count: results of TIMI-10B. Presented at the 70^th Scientific Session of the American Heart Association, November 9-12, 1997, Orlando, Florida.
36 Gibson M, Cannon C.P, McCabe C, Van de Werf F, Braunwald E. A randomized prospective comparison of TPA with TNK using the TIMI frame count: results of TIMI 10B. Circulation 1997; 96 suppl. I 1-330-1.
37 Lerakis S, Stouffer G.A, Runge M.S. New thrombolytics: What is under development?. Bio Drugs 1997; 8: 24-32.
38 Ogata N, Ogata Y, Hokamaki J. et al. Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction: Comparison between thrombolytic therapies with mutant TPA (lanoteplase/BMS-200980) and recombinant TPA (alteplase). Circulation 1996; 94 suppl. I 1-89.
39 Thadani U. Lanoteplase: The In TIME Study. Presented at Myocardial Reperfusion X: Concepts and Controversies, March 14,1997, Anaheim, CA.
40 Liao W.C, Beierle F.A, Stouffer B.C. et al. Single bolus regiment of lanoteplase (nPA) in acute myocardial infarction: Pharmacokinetic evaluation from InTime-I study. Circulation 1997; 96 suppl. I 1-260-1.
41 Lundergan C.F, Reiner J.S, McCarthy W.F, Coyne K.S, Califf R.M, Ross A.M. for the GUSTO-I Investigators. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. J Am Coll Cardiol 1998; 32: 641-7.
42 Collen D, Stock L, LaCroix H, Suy R, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. IV: identification of variants with reduced antibody induction but intact potency. Circulation 1997; 95: 463-72.
43 Vanderschueren S, Barrios L, Kerdsinchai P. et al. for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-9.
44 Gulba D.C, Bode C, Runge M.S, Huber K. Thrombolytic agents - an overview. Ann Hematol 1996; 73 suppl. I S9-S27.
45 Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Med 1998; 4: 279-84.
46 Collen D, Vanderschueren S, Van de Werf F. Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Haemostasis 1996; 26 (04) 294-300.
47 Collen D, Moreau H, Stock L, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. II: thrombolytic properties and antibody induction. Circulation 1996; 94: 207-16.
48 Van de Werf F. New fibrinolytic landscape (TNK, nPA, staphylokinase). Presented at Myocardial Reperfusion XI: Concepts and Controversies, Satellite symposium at the 46^th Annual Scientific Session of the American College of Cardiology, March 28, 1998, Atlanta, Georgia.
49 Gardell S.J, Ramjit D.R, Stabilito I.I. et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-53.
50 Meilott M.J, Stabilito I.I, Holahan M.A. et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992; 12: 212-21.
51 Montoney M, Gardell S.J, Marder V.J. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-4.
52 Antman E.M, Giugliano R.P, Gibson C.M, McCabe C.H, Coussement P, Kleiman N.S, Vahanian A, Adgey A.A, Menown I, Rupprecht H.J, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-32.
53 Ross A.M. The Plasminogen Activator-Angioplasty Compatibility Trial (PACT). J Amer Coll Cardiol. Im Druck.
54 Neuhaus K.L, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19: 885-91.